MDT

95.96

+0.52%↑

VEEV

289.99

+1.8%↑

145.28

+0.97%↑

HQY

96.18

+3.59%↑

TLRY

1.5

-4.46%↓

MDT

95.96

+0.52%↑

VEEV

289.99

+1.8%↑

145.28

+0.97%↑

HQY

96.18

+3.59%↑

TLRY

1.5

-4.46%↓

MDT

95.96

+0.52%↑

VEEV

289.99

+1.8%↑

145.28

+0.97%↑

HQY

96.18

+3.59%↑

TLRY

1.5

-4.46%↓

MDT

95.96

+0.52%↑

VEEV

289.99

+1.8%↑

145.28

+0.97%↑

HQY

96.18

+3.59%↑

TLRY

1.5

-4.46%↓

MDT

95.96

+0.52%↑

VEEV

289.99

+1.8%↑

145.28

+0.97%↑

HQY

96.18

+3.59%↑

TLRY

1.5

-4.46%↓

Home・Lista de Ações・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Abrir

SetorSaúde

15.19 1.4

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

14.88

Máximo

15.25

Indicadores-chave
By Trading Economics
Rendimento	222M 227M
Vendas	-23M 139M
P/E Médio do Setor	5.808 36.442
Margem de lucro	163.843
Funcionários	1,780
EBITDA	6.3M 1.3M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+28.01% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-22M 2.7B
Abertura anterior	13.79
Fecho anterior	15.19

Sentimento de Notícias

By Acuity

50%

160 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

14.24 / 14.78 Suporte e Resistência

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de out. de 2025, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

20 de out. de 2025, 23:43 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de out. de 2025, 23:36 UTC

Conversa de Mercado

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

20 de out. de 2025, 22:14 UTC

Conversa de Mercado

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

20 de out. de 2025, 22:00 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

20 de out. de 2025, 21:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

20 de out. de 2025, 20:56 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20 de out. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

20 de out. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

20 de out. de 2025, 20:38 UTC

Ganhos

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

20 de out. de 2025, 20:38 UTC

Ganhos

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

20 de out. de 2025, 20:38 UTC

Ganhos

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

20 de out. de 2025, 20:36 UTC

Ganhos

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

20 de out. de 2025, 20:36 UTC

Ganhos

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

20 de out. de 2025, 20:36 UTC

Ganhos

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

20 de out. de 2025, 20:36 UTC

Ganhos

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

20 de out. de 2025, 20:16 UTC

Conversa de Mercado

Canada Labor-Market Indicators Lean Dovish -- Market Talk

20 de out. de 2025, 20:05 UTC

Ganhos

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

20 de out. de 2025, 19:39 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

20 de out. de 2025, 19:34 UTC

Conversa de Mercado

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

20 de out. de 2025, 19:32 UTC

Conversa de Mercado

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

20 de out. de 2025, 19:00 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20 de out. de 2025, 18:29 UTC

Conversa de Mercado

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

20 de out. de 2025, 18:11 UTC

Conversa de Mercado

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

20 de out. de 2025, 18:04 UTC

Conversa de Mercado

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

20 de out. de 2025, 17:03 UTC

Conversa de Mercado

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

20 de out. de 2025, 17:01 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de out. de 2025, 17:01 UTC

Conversa de Mercado

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

20 de out. de 2025, 16:43 UTC

Conversa de Mercado

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

20 de out. de 2025, 16:25 UTC

Conversa de Mercado

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

28.01% parte superior

Previsão para 12 meses

Média 19.38 USD 28.01%

Máximo 25 USD

Mínimo 13.75 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

2 ratings

Comprar

Manter

Vender

Com base em 2 analistas que deram avaliações de ações para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

14.24 / 14.78Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimento

By Acuity

160 / 371 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.